2-[(Carboxymethyl)sulfanyl]-4-oxo-4-arylbutanoic acids selectively suppressed proliferation of neoplastic human HeLa cells. A SAR/QSAR study

被引:15
作者
Drakulic, BJ
Juranic, ZD
Stanojkovic, TP
Juranic, IO
机构
[1] Inst Chem Technol & Met, Belgrade 11000, Serbia Monteneg
[2] Univ Belgrade, Fac Chem, Belgrade 11000, Serbia Monteneg
[3] Inst Oncol & Radiol Serbia, Belgrade, Serbia Monteneg
关键词
D O I
10.1021/jm0502889
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of twenty alkyl-, halo-, and methoxy-aryl-substituted 2-[(carboxymethyl)sulfanyl]-4-oxo-4-arylbutanoic acids were synthesized. The new compounds, called CSAB, suppressed proliferation of human cervix carcinoma, HeLa cells, in vitro in a concentration range of 0.644 to 29.48 mu M/L. Two compounds exhibit antiproliferative activity in sub-micromolar concentrations (16, 19). Five compounds act in low micromolar concentrations (< 2 mu M/L). The most active compounds exert lower cytotoxicity toward healthy human peripheral blood mononuclear cells (PBMC and PBMC+PHA) (selectivity indexes > 10). A strong structure-activity relationship, using estimated log P values and BCUT descriptors, was observed.
引用
收藏
页码:5600 / 5603
页数:4
相关论文
共 20 条
[1]   SULFHYDRYL ENZYME INACTIVATION BY NICOTINOYLACRYLATES [J].
ANDERSON, BM ;
ANDERSON, CD ;
DONZELLI, G ;
DALPOZZO, A .
BIOCHIMICA ET BIOPHYSICA ACTA, 1984, 787 (03) :215-220
[2]   SELECTIVE ENZYME INACTIVATION BY BENZOYLACRYLIC ACID-DERIVATIVES [J].
ANDERSON, BM ;
TANCHOCO, ML ;
DALPOZZO, A .
BIOCHIMICA ET BIOPHYSICA ACTA, 1982, 703 (02) :204-211
[3]  
DRAKULIC B, 2002, 3 INT C SE EUR COUNT, P189
[4]  
DRAKULIC BJ, 2002, 3 INT C SE EUR COUNT, P229
[5]   ATOMIC PHYSICOCHEMICAL PARAMETERS FOR 3-DIMENSIONAL-STRUCTURE-DIRECTED QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS .2. MODELING DISPERSIVE AND HYDROPHOBIC INTERACTIONS [J].
GHOSE, AK ;
CRIPPEN, GM .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1987, 27 (01) :21-35
[6]  
GIELDANOWSKI J, 1981, ARCH IMMUNOL THER EX, V29, P257
[7]  
Juranic Z, 1999, J SERB CHEM SOC, V64, P505
[8]  
Juranic Z, 1998, J EXP CLIN CANC RES, V17, P33
[9]  
KAMEO K, 1988, CHEM PHARM BULL, V36, P2050
[10]  
KAWASHIMA Y, 1992, CHEM PHARM BULL, V40, P774